Glyceryltriacetate for Breathing Improvement via Acetylation
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current treatments for breathing difficulties associated with reduced lung function, such as those caused by lung diseases or viral infections like COVID-19, have shown limited therapeutic benefit, and glyceryltriacetate (GTA) has not progressed beyond preclinical stages for clinical use.
Innovation Solution
GTA is administered daily in effective amounts to improve breathing by increasing acetate blood levels and tissue bioavailability, enhancing acetylation capabilities, and stabilizing lung endothelial cells, thereby addressing breathing difficulties through its use in nutraceutical or pharmaceutical compositions.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Ease of operation
If GTA is administered alone for breathing difficulty treatment, then the treatment simplicity is maintained, but the therapeutic effect is insufficient
Solution Approach 1:
The patent combines GTA with other therapeutic agents (such as chemotherapy drugs like temozolomide) to create a composite treatment regimen. This merging approach allows the treatment to maintain simplicity of administration while achieving enhanced therapeutic effects through the synergistic action of multiple agents working together.
2Reliability
If high doses of GTA are administered to achieve therapeutic effect, then the breathing improvement is enhanced, but the risk of side effects increases
Solution Approach 1:
The patent optimizes the dosage parameters of GTA by determining effective dose ranges that achieve therapeutic breathing improvement while minimizing toxicity. This involves adjusting concentration, frequency, and duration of administration to find the optimal parameter window where beneficial effects are maximized and harmful effects are minimized.
Solution Approach 2:
The patent uses combination therapy where GTA acts as an intermediary or adjuvant agent that enhances the effectiveness of other primary treatments while allowing lower doses of each individual agent, thereby reducing side effects while maintaining or improving therapeutic outcomes.
3Adaptability or versatility
If GTA treatment is extended to clinical trial stage, then the potential therapeutic benefit is expanded, but the development time and cost increase
Solution Approach 1:
The patent conducts comprehensive preclinical studies including in vitro and in vivo experiments to thoroughly evaluate GTA's safety, pharmacokinetics, and efficacy before initiating clinical trials. This preliminary action ensures that when clinical trials do commence, they are based on robust data, potentially reducing the need for extensive early-phase trials and accelerating the overall development timeline.
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
GTA effectively improves breathing in subjects with reduced lung function by enhancing acetylation power, preventing lung injury, and stabilizing microtubules, as demonstrated in various examples including COVID-19 and asthma patients, with noticeable improvements in lung function parameters.
Implementation Method 1
enhancing acetylation capabilities
Implementation Method 2
stabilizing microtubules
Data Source
AI summary
The present disclosure relates to glyceryltriacetate (GTA) compound for use in improving breathing in a subject experiencing a bathing difficulty. Of particular interest is the use of GTA for treating reduced lung function, such as that caused by lung infection and/or lung inflammation. Also disclosed is thus a composition and method for improving breathing of a subject experiencing a breathing difficulty.